06-May-2015 - QIAGEN N.V.

QIAGEN partners with sequencing provider

QIAGEN N.V. announced that it has expanded its relationship with BG to provide QIAGEN’s Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.
Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis‘ secure, cloud-based environment and gain access to its leading comprehensive gene variant data and genomic interpretation applications
“We are very pleased to expand QIAGEN’s relationship with BGI, the global leader in sequencing services. Integrating Ingenuity Variant Analysis into BGI’s highly reliable sequencing services will enable clients to accelerate workflows. They’ll be able to transform large quantities of genomic data into valuable molecular insights for research or clinical applications,” said Laura Furmanski, Head of QIAGEN’s Bioinformatics Business Area. “Bioinformatics solutions from QIAGEN are growing rapidly as scientists and healthcare professionals increasingly use genomic information to guide research and provide precise diagnosis for medical decision-making. We are committed to working with leading organizations such as BGI to make these improvements in life possible.”

Facts, background information, dossiers
  • Qiagen
  • BGI
  • bioinformatics
  • sequencing services
More about Qiagen
  • News

    QIAGEN announces CEO leadership transition

    QIAGEN N.V. announced that Peer M. Schatz, Chief Executive Officer, has notified the Company that, after 27 years at QIAGEN, he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Special Advisor to the Supervisory Board an ... more

    QIAGEN acquires Spanish diagnostics start-up company

    QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ... more

    QIAGEN joins CANCER-ID consortium for liquid biopsy workflows

    QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer. Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through ... more

More about Beijing Genomics Institute